Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lee, Ju Yeon ^a   Lee, Hyun Tae ^a   Shin, Woori ^a   Chae, Jongseok ^a   Choi, Jaemo ^a   Kim, Sung Hyun ^a   Lim, Heejin ^a   Won Heo, Tae ^a   Park, Kyeong Young ^a   Lee, Yeon Ji ^a   Ryu, Seong Eon ^b   Son, Ji Young ^a   Lee, Jee Un ^a   Heo, Yong Seok ^a  

^a Konkuk University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN F(AB) FRAGMENT; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; BMS-936559; EPITOPE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BINDING;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; CRYSTAL STRUCTURE; DISEASE TREATMENT; IMMUNE RESPONSE; IMMUNITY;

ARTICLE; CANCER IMMUNOTHERAPY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG APPROVAL; HODGKIN DISEASE; KIDNEY CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; CONFORMATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR MODEL; MOUSE; NEOPLASM; PROCEDURES; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HUMANS; IMMUNOTHERAPY; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84994057015     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13354     Document Type: Article

References (52)

1. Chen, L., Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Immunol. Rev. 13, 227-242 (2013).
2. Greenwald, R. J. et al. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
3. Zou, W. et al. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467-477 (2008).
4. Lenschow, D. J., Walunas, T. L., Bluestone, J. A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
5. Greenfield, E. A., Nguyen, K. A., Kuchroo, V. K. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18, 389-418 (1998).
6. Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B., Sharpe, A. H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11, 294-300 (1999).
7. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
8. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
9. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
10. Buchbinder, E. I., Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98-106 (2016).
11. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
12. Segal, N. H. et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 68, 889-892 (2008).
13. Chen, D. S., Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
14. Rizvi, N. A. et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
15. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
16. Sharma, P., Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
17. Topalian, S. L. et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27, 450-461 (2015).
18. Wolchok, J. D., Chan, T. A. Cancer: antitumour immunity gets a boost. Nature 515, 496-498 (2014).
19. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
20. Chen, L., Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present and future. J. Clin. Invest. 125, 3384-3391 (2015).
21. Gunturi, A., McDermott, D. F. Nivolumab for the treatment of cancer. Expert Opin. Invest. Drugs 24, 253-260 (2015).
22. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
23. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
24. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
25. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
26. Callahan, M. K., Postow, M. A., Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity 44, 1069-1078 (2016).
27. Ostrov, D. A., Shi, W., Schwartz, J. C., Almo, S. C., Nathenson, S. G. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science 290, 816-819 (2000).
28. Stamper, C. C. et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611 (2001).
29. Schwartz, J. C., Zhang, X., Fedorov, A. A., Nathenson, S. G., Almo, S. C. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410, 604-608 (2001).
30. Zak, K. M. et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23, 2341-2348 (2015).
31. Cheng, X. et al. Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 288, 11771-11785 (2013).
32. Lazar-Molnar, E. et al. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl Acad. Sci. USA 105, 10483-10488 (2008).
33. Lin, D. Y. et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011-3016 (2008).
34. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
35. Sunshine, J., Taube, J. M. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23, 32-38 (2015).
36. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., Honjo., T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212-1218 (2013).
37. Comin-Anduix, B., Escuin-Ordinas, H., Ibarrondo, F. J. Tremelimumab: research and clinical development. Onco. Targets Ther. 9, 1767-1776 (2016).
38. Yu, C. et al. Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering. J. Biol. Chem. 286, 6685-6696 (2011).
39. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
40. Larkin, J., Hodi, F. S., Wolchok, J. D. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 1270-1271 (2015).
41. Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950-959 (2015).
42. Hu, S. et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor a-associated diseases from a molecular view. J. Biol. Chem. 288, 27059-27067 (2013).
43. Carreno, B. M., Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53 (2002).
44. Schonfeld, D. et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl Acad. Sci. USA 106, 8198-8203 (2009).
45. Anton van der Merwe, P., Davis, S. J., Shaw, A. S., Dustin, M. L. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin. Immunol. 12, 5-21 (2000).
46. Sasikumar, P. G. N. et al. Immunosuppression modulating compounds. EP2585099 A2 (2013).
47. Sasikumar, P. G. N., Ramachandra, M., Naremaddepalli, S. S. S. Peptidomimetic compounds as immunomodulators. WO2013132317 A8 (2013).
48. Miller, M. M. et al. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions. US20140294898 A1 (2014).
49. Sasikumar, P. G. N., Ramachandra, M., Naremaddepalli, S. S. S. 1, 2, 4-oxadiazole derivatives as immunomodulators. US20150073024 A1 (2015).
50. Chupak, L. S., Zheng, X. Compounds useful as immunomodulators. WO2015034820 A1 (2015).
51. Zak, K. M. et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7, 30323-30335 (2016).
52. Emsley, P., Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).